NextFin News - Veritas Capital agreed to buy Bodycote Plc for about £1.65 billion ($2.2 billion), raising its offer to 940 pence a share in cash to outbid rival CVC Advisers and win control of the British heat-treatment specialist. The deal, announced Tuesday, values Bodycote at £1.85 billion including debt and lands one day before the Sept. 2 deadline the two private equity firms faced under UK takeover rules to either table a firm bid or walk away.
The all-cash offer of 940 pence a share is roughly 25% above the 750 pence Bodycote fetched before the auction became public in August, and about 6% above the 885 pence Apollo Global Management was prepared to pay before it withdrew from the process in June. For Veritas, the prize is the world's largest provider of thermal processing services - a network of heat-treatment and metal-processing facilities that sit inside aerospace, defense, energy and automotive supply chains, where switching costs are high and certification barriers keep competitors out.
The Auction That Priced the Deal Before Veritas Moved
The final number did not appear out of nowhere. Bodycote confirmed on Aug. 5 that it had received competing conditional cash proposals from CVC and Veritas, each valuing the company at roughly £1.56 billion. CVC's opening bid stood at 915 pence a share - 907.8 pence in cash plus a 7.2 pence permitted interim dividend - while Veritas came in one penny lower at 914 pence. The board said then that it would be minded to recommend either offer, subject to due diligence, and granted both bidders access to confirmatory due diligence on an expedited timetable.
What happened next is the clearest read on where the market thought the price was going. Bodycote touched an intraday high of 927.5 pence on Aug. 5 and closed that session at 923 pence, above both initial offers. For the rest of August the stock traded in the low 900s - 913 pence at the Aug. 28 close - meaning the market spent nearly a month pricing in a higher bid. Veritas's 940 pence move is a 2.9% premium to that Aug. 28 close. It cleared the board's threshold, but only just: the auction had already done most of the price discovery.
The contest also reverses a setback from June, when Apollo Global Management said it did not intend to make a firm offer and ended discussions over a proposal valued at about £1.52 billion. Three bidders in roughly four months for the same FTSE 250 industrial is not a coincidence; it is evidence that sellers are winning price discovery by running competitive processes rather than granting exclusivity, and that private equity is circling UK mid-caps with defense and aerospace exposure.
The mechanics of that process matter. Under Rule 2.4 of the UK Takeover Code, a potential bidder must either announce a firm intention to make an offer or withdraw within 28 days of being named - unless the target consents to an extension. Bodycote's board did not grant exclusivity to any single bidder, kept both CVC and Veritas engaged, and let the Sept. 2 deadline act as a forcing function. Deadlines convert months of due diligence into a binary decision, and they remove the option to wait for a better macro backdrop. Veritas moved one day before the wire.
What Veritas Is Actually Buying
At 940 pence, the offer prices Bodycote at roughly 21 times adjusted 2025 earnings of 44.4 pence, and about 14.4 times the £114.3 million of adjusted operating profit on an equity value of £1.65 billion. For a business with recurring industrial service revenue and a growing aerospace and defense backlog, that is not cheap - but it is not extravagant for a market-leading platform with high switching costs.
The financial profile explains both the interest and the risk. Bodycote's full-year 2025 revenue was £727.1 million, down 4.0% from £757.1 million, with adjusted operating profit of £114.3 million versus £129.0 million in 2024. Adjusted operating margin compressed by 130 basis points, and adjusted basic earnings per share fell to 44.4 pence from 48.6 pence. Yet the decline was not uniform: core revenue was broadly stable organically, down just 0.3% to £671.6 million, and the second half grew 3.2% year on year against a first-half decline of 3.5%. Statutory operating profit rose to £83.6 million from £37.9 million on lower exceptional charges, and the company announced an £80 million share buyback, expected to complete by the end of 2027.
The margin pressure had a name: the Optimise programme. It is a cost and efficiency initiative aimed at lifting the operating margin toward the company's medium-term target, and it delivered about £4 million of savings in 2025. That is real progress, but it is small against a £14.7 million drop in adjusted operating profit - which is exactly why a private equity buyer with an operational improvement playbook sees opportunity. Under new ownership, the Optimise benefits either scale, in which case the deal underwrites itself, or they stall, in which case the 21-times earnings entry multiple becomes the high watermark.
The end-market mix is doing the heavy lifting on the revenue side. Aerospace & Defence and Industrial Gas Turbines accelerated through 2025, offsetting weakness in automotive, industrial markets and softening oil & gas demand. That is a structural tailwind: commercial aerospace production is climbing back toward pre-pandemic rates, defense budgets across NATO are rising toward and beyond the 2% of GDP floor, and gas turbines sit at the center of both power-generation investment and the energy-transition bridge. Heat treatment is not a discretionary spend - a turbine blade or landing-gear component must be processed to specification before it can fly, and Nadcap accreditation keeps lower-tier competitors out.
Bodycote has been positioning for exactly this mix shift. In early 2026 it completed the acquisition of Spectrum Thermal Processing, a Nadcap-accredited aerospace and defense heat-treatment provider based in Rhode Island, for approximately $8 million - a small deal in absolute terms, but one that extends its North American footprint in the fastest-growing segment. It also disposed of ten non-core sites in France during 2025, pruning the portfolio toward higher-quality assets. A buyer looking at Bodycote is not buying a static industrial conglomerate; it is buying a portfolio that management has already started to reshape.
That is why this deal is better understood as a bet on the defense-aerospace cycle than as a generic UK value play. Veritas, which says it invests "at the intersection of technology and government" and reports more than $50 billion of assets under management as of June 30, 2026, has spent the year putting a freshly raised $15.3 billion fund to work in government technology and critical infrastructure. Bodycote fits the mandate: a regulated, government-influenced industrial with pricing power in its strongest segments.
But there is a tension the headline multiple hides. Bodycote's overall revenue fell 4% in 2025, and the Optimise cost program delivered about £4 million of savings in the year. Veritas is not buying a company at peak earnings and hoping for multiple expansion. It is buying one where the earnings trough may be behind it, and where the return case depends on volume recovery plus cost execution.
Cyclical Entry Price, Structural Asset - and the Risk of Confusing the Two
This is the judgment the rest of the analysis rests on, and the two halves should not be conflated. The reason private equity is interested in Bodycote right now is cyclical: UK mid-cap valuations have been depressed relative to US and European peers, sterling has been weak enough to make British assets attractive to dollar buyers, and the broader European M&A market is thawing after a two-year freeze. A buyer can argue it is acquiring pound-denominated cash flows at a discount to global replacement cost, and that the exit multiple will expand when the UK mid-cap discount narrows. That is a mean-reversion trade. Mean reversion is, by definition, cyclical - it works because prices revert, not because the world has changed.
The reason Bodycote's cash flows are defensible, however, is structural. Aerospace and defense are not cycling back to a prior normal; they are resetting to a higher plateau. NATO members are lifting defense spending, commercial aircraft backlogs remain historically large, and gas-turbine demand spans both grid investment and energy security. Heat treatment is a process step with high qualification barriers - once a supplier is certified into an aerospace or defense supply chain, it is expensive and slow to replace. That is a structural moat, and it is why the earnings trough is likely behind the company even if the industrial cycle wobbles.
So the cleanest framing of the deal is this: Veritas is using a cyclical entry price - a depressed UK mid-cap, a competitive but contained auction - to buy a structural asset. The risk is that the two get confused - that the buyer pays a structural price for what turns out to be a cyclical recovery, or that the cyclical multiple compression it is counting on never arrives because UK mid-caps stay cheap for structural reasons of their own.
The company's own guidance sits squarely in the middle of that tension. Chief Executive Jim Fairbairn said in the 2025 results statement:
In 2026 we expect to deliver Core organic revenue growth, supported by continued strong demand in Aerospace & Defence and Industrial Gas Turbines. Conditions in Automotive and Industrial Markets are expected to remain challenging in the near term.
Management, in other words, is underwriting growth from the structural side of the business while warning that the cyclical side has not turned.
The financing environment is the third variable. A £1.85 billion debt-inclusive buyout in 2026 does not look like a 2021 deal. Leveraged-loan spreads remain elevated by historical standards, lenders are discriminating, and covenant structures have tightened since the cheap-money era. That cuts both ways: it disciplines what a buyer can pay - which is part of why Veritas's final bid only edged past the market's expectation - but it also means any acquisition must generate enough cash flow to service debt without relying on multiple expansion at exit. For Veritas, the return math has to come from EBITDA growth, not from financial engineering.
The Counter-Thesis: Not Too Expensive, Just Too Tight
The strongest case against this deal is not that 940 pence is too high in isolation. It is that the offer leaves almost no margin for error on the operating side. At roughly 21 times adjusted earnings, Veritas is underwriting a meaningful acceleration from a company whose revenue fell 4% last year and whose margin compressed. The Optimise program's £4 million of 2025 savings is a start, not a transformation. If automotive and industrial demand in Europe stays soft - and the company itself warned those conditions would remain challenging in the near term - then the volume recovery Veritas needs may take longer than the debt math allows.
There is also a financing risk the headline equity value obscures. The £1.65 billion equity check is only part of the capital structure; including debt, the deal is worth £1.85 billion. In an environment where leveraged-loan spreads remain elevated and lenders are discriminating, a buyout at this size needs stable, growing cash flow to service debt - not a hope that end markets turn. If Bodycote's 2026 core organic growth disappoints, or if adjusted operating margin fails to expand beyond the 2025 level of about 15.7%, the equity return case compresses quickly.
The specific signal that would prove the bull case wrong is concrete: Bodycote's first-half 2026 update showing core organic revenue growth turning negative again, or adjusted operating margin falling below roughly 15%. Either outcome would indicate that aerospace and defense strength is not enough to offset the cyclical drag elsewhere - and that Veritas bought the top of a cycle it assumed was already behind.
Who Benefits, Who Is Exposed, and What Comes Next
For Bodycote shareholders, the outcome is straightforward: a 940 pence cash exit that rewards patience through a contested process, roughly 25% above the pre-auction price and 6% above where Apollo left the bidding. For Veritas, the outcome is a platform asset with structural end-market exposure, bought at a price that demands operational execution rather than financial engineering alone.
The wider implication is for the UK mid-cap market. If this deal clears regulatory review and completes, it becomes a template: defense- and aerospace-exposed industrials on the London market, trading at a discount to global peers, are acquirable - and private equity has the capital and the appetite to prove it. The exposed parties are the boards of similar FTSE 250 companies that have not yet run a competitive process; the beneficiaries are their shareholders.
The forward look splits cleanly by horizon. In the short term, expect more auction activity in UK industrials with government or defense exposure - the Bodycote process telegraphs that sellers can extract full price by keeping multiple bidders engaged to the Rule 2.4 deadline. In the medium term, the test is Bodycote's operating delivery under private ownership: whether Optimise savings scale and whether aerospace and defense volumes keep growing fast enough to offset automotive and industrial weakness. In the long term, the structural case stands or falls on defense budgets and aerospace production rates - and on whether heat treatment remains a bottleneck service with pricing power as those industries scale.
Base case: the deal completes near 940 pence, Bodycote delivers low-single-digit core organic growth in 2026 as aerospace and defense offset industrial weakness, and Veritas holds the asset through the cycle for a later exit. Upside case: European industrial demand recovers faster than expected, margin expansion accelerates, and the UK mid-cap discount narrows - a double benefit. Downside case: a deeper European industrial slowdown keeps volumes weak, debt costs bite, and the roughly 21-times earnings entry multiple proves to be the high watermark for the stock.
Veritas did not overpay for Bodycote's past - it paid for a defense-aerospace future that is already partly priced in. The deal only wins if the structural tailwind outruns the cyclical drag.
Explore more exclusive insights at nextfin.ai.
